Laura Rosa Magni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3103932/publications.pdf

Version: 2024-02-01

567281 501196 30 859 15 28 citations h-index g-index papers 30 30 30 1551 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Aberrant Structural Connectivity of the Triple Network System in Borderline Personality Disorder Is Associated with Behavioral Dysregulation. Journal of Clinical Medicine, 2022, 11, 1757.	2.4	1
2	Symptomatic Disorders in Adults and Adolescents With Borderline Personality Disorder. Journal of Personality Disorders, 2021, 35, 48-55.	1.4	8
3	Affective and Behavioral Characteristics of Adolescent and Adult Borderline Personality Disorder. Journal of Personality Disorders, 2021, 35, 131-141.	1.4	4
4	Risk Factors for Borderline Personality Disorder in Adolescents. Journal of Personality Disorders, 2020, 34, 17-24.	1.4	8
5	Sexual Orientation and Gender of Intimate Relationship Partners Among Adolescents With BPD and Psychiatrically Healthy Adolescents. Journal of Personality Disorders, 2020, 35, 1-7.	1.4	1
6	Parameters of reported childhood sexual abuse and assault in adolescents and adults with borderline personality disorder. Personality and Mental Health, 2020, 14, 254-262.	1.2	5
7	Neurobiological and clinical effect of metacognitive interpersonal therapy vs structured clinical model: study protocol for a randomized controlled trial. BMC Psychiatry, 2019, 19, 195.	2.6	4
8	Wholeâ€brain microstructural white matter alterations in borderline personality disorder patients. Personality and Mental Health, 2019, 13, 96-106.	1.2	10
9	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. Psychiatry Research - Neuroimaging, 2019, 283, 118-124.	1.8	33
10	Factors associated with first-versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS ONE, 2018, 13, e0201371.	2.5	44
11	Psychosocial functioning in adolescents with and without borderline personality disorder. Personality and Mental Health, 2017, 11, 164-170.	1.2	18
12	Prevalence rates of borderline symptoms reported by adolescent inpatients with BPD, psychiatrically healthy adolescents and adult inpatients with BPD. Personality and Mental Health, 2017, 11, 150-156.	1.2	25
13	Prevalence rates of childhood protective factors in adolescents with BPD, psychiatrically healthy adolescents and adults with BPD. Personality and Mental Health, 2017, 11, 189-194.	1.2	11
14	Effects of cognitive remediation therapy on neurocognition and negative symptoms in schizophrenia: an Italian naturalistic study. Cognitive Neuropsychiatry, 2017, 22, 53-68.	1.3	6
15	Prevalence and severity of childhood adversity in adolescents with BPD, psychiatrically healthy adolescents, and adults with BPD. Personality and Mental Health, 2017, 11, 171-178.	1.2	25
16	Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs. Revista Brasileira De Psiquiatria, 2017, 39, 244-251.	1.7	11
17	Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiology and Psychiatric Sciences, 2016, 25, 532-540.	3.9	46
18	First-generation antipsychotics and QTc: any role for mediating variables?. Human Psychopharmacology, 2016, 31, 313-318.	1.5	24

#	Article	IF	CITATIONS
19	Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval. PLoS ONE, 2016, 11, e0148212.	2.5	50
20	Abnormalities in Cortical Gray Matter Density in Borderline Personality Disorder. European Psychiatry, 2015, 30, 221-227.	0.2	19
21	Violent behavior of patients living in psychiatric residential facilities: A comparison of male patients with different violence histories. International Journal of Law and Psychiatry, 2015, 39, 46-51.	0.9	11
22	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of Affective Disorders, 2015, 180, 179-184.	4.1	267
23	Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine. Acta Psychiatrica Scandinavica, 2015, 131, 408-416.	4.5	6
24	The effect of service satisfaction and spiritual well-being on the quality of life of patients with schizophrenia. Psychiatry Research, 2014, 216, 185-191.	3.3	20
25	Paroxetine versus other anti-depressive agents for depression. The Cochrane Library, 2014, , CD006531.	2.8	30
26	Structural brain features of borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2013, 213, 83-91.	1.8	43
27	Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Library, 2013, , CD004185.	2.8	97
28	Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial. Trials, 2013, 14, 323.	1.6	8
29	Burnout in Nonhospital Psychiatric Residential Facilities. Psychiatric Services, 2009, 60, 1547-1551.	2.0	8
30	Personality Traits in an Italian Sample: Relationship with Anxiety and Depression. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 26-30.	1.2	16